Advancing cancer care through precision diagnostics, genomic intelligence and personalised medicine.
At Shansons Precix, we are working towards a future where healthcare decisions are informed by the unique biological and genetic characteristics of every individual. Our focus brings together genomics, molecular diagnostics, pharmacogenetics, next-generation sequencing, liquid biopsy, bioinformatics and personalised therapeutic research.
Traditional healthcare has often relied on population-level averages to guide diagnosis and treatment. However, every patient is biologically different.
Genetic variation, molecular characteristics and individual disease biology can influence disease susceptibility, treatment response and the likelihood of adverse effects. Precision medicine changes this approach.
By studying the biological and genetic characteristics of an individual, healthcare can move towards more informed approaches to:
We believe the next generation of healthcare will be driven by the ability to understand disease at an increasingly precise biological level. Our scientific philosophy is built around five principles:
Study the molecular and genetic characteristics underlying disease biology.
Identify clinically and biologically relevant biomarkers and genetic alterations.
Convert complex genomic information into meaningful biological insights.
Use individual-level information to support more personalised healthcare strategies.
Translate research and technological progress into practical precision medicine applications.
Precision medicine requires seamless integration across each stage of biological processing, high-throughput sequencing, and computational intelligence.
Personalised healthcare approaches based on individual genetic and molecular characteristics. Bringing together genomic data and disease-specific knowledge.
Comprehensive characterisation of germline variants and somatic alterations across oncogenic panels and whole exomes.
Learn more about NGS →Understanding how individual genetic polymorphisms in drug metabolism enzymes influence treatment response and toxicity.
Explore Pharmacogenetics →Minimally invasive blood-based investigation of circulating tumour DNA (ctDNA) for real-time cancer monitoring.
Discover Liquid Biopsy →High-throughput sequencing enabling rapid, comprehensive multi-gene profiling and mutation identification.
Explore Sequencing Platforms →Turning massive genomic datasets into biological insight through deep learning and automated variant interpretation.
Read about Computational Biology →Designing the future of personalised cancer immunity by mapping patient-specific neoantigens and immune pathways.
Explore Vaccine Research →Comprehensive development programs advancing cancer genomics, non-invasive profiling, and AI.
Develop a research framework for analysing cancer-associated genomic alterations and molecular patterns.
Explore blood-based approaches for identifying cancer-associated molecular signals and ctDNA dynamics.
Investigate relationships between inherited genetic variation and individual differences in treatment response.
The future of medicine is fundamentally shifting from reactive population-average treatments to proactive, data-driven personalized care.
rather than reaction to advanced disease symptoms.
rather than late-stage discovery when options are limited.
rather than diagnosis based only on anatomy and symptoms.
rather than empirical population-average therapy.
rather than isolated, one-time episodic assessments.
rather than fragmented, isolated clinical information.
Core questions regarding precision medicine, genomic profiling, and our research scope.
